SCHEMBL3250405

SCHEMBL3250405

COc1ccc(S(=O)(=O)NCCC(=O)Nc2ccc(Cl)cc2Cc2c(F)cccc2F)cc1OC

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NPC1 O15118 1/20 0.48
ALDH1A1 P00352 5/20 0.48
MAPT P10636 3/20 0.47
TP53 P04637 2/20 0.47
F2 P00734 1/20 0.47
L3MBTL1 Q9Y468 2/20 0.47
ATM Q13315 1/20 0.47
LMNA P02545 2/20 0.47
HTT P42858 2/20 0.47
MEN1 O00255 1/20 0.46
KMT2A Q03164 1/20 0.46
ALPL P05186 1/20 0.44
MAPK1 P28482 1/20 0.43
PKM P14618 1/20 0.43
PSMD14 O00487 1/20 0.43
APAF1 O14727 1/20 0.43
POLB P06746 1/20 0.43
GRK2 P25098 1/20 0.43
BCL2L1 Q07817 1/20 0.43
MCL1 Q07820 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3256517 0.91 ALDH1A1 (0.51) ALDH1A1MAPTTP53F2LMNA
SCHEMBL4867720 0.88 ALDH1A1 (0.49) ALDH1A1MAPTTP53F2KMT2A
SCHEMBL4863941 0.87 ALDH1A1 (0.48) ALDH1A1MAPTTP53F2LMNA
SCHEMBL3246071 0.83 ALDH1A1 (0.61) ALDH1A1MAPTTP53LMNAHTT
SCHEMBL3253072 0.83 MEP1B (0.52) ALDH1A1MAPTF2LMNAKMT2A
SCHEMBL3252976 0.83 ALDH1A1 (0.49) ALDH1A1MAPTTP53F2L3MBTL1
SCHEMBL4863480 0.82 ALDH1A1 (0.53) ALDH1A1MAPTTP53F2L3MBTL1
SCHEMBL3249493 0.82 MAPK1 (0.51) ALDH1A1MAPTTP53F2LMNA
SCHEMBL3253388 0.82 MEP1B (0.53) ALDH1A1MAPTTP53F2LMNA
SCHEMBL3254908 0.81 MEP1B (0.50) ALDH1A1MAPTF2LMNAHTT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1776347-B1 SULPHONAMIDE DERIVATIVES, THEIR PREPARATION AND THEIR THERAPEUTIC APPLICATION SANOFI AVENTIS (FR) 2010-05-26 EP disclosed
US-7396958-B2 Sulphonamide derivatives, their preparation and their therapeutic application SANOFI AVENTIS (FR) 2008-07-08 US disclosed
US-20070185136-A1 SULPHONAMIDE DERIVATIVES, THEIR PREPARATION AND THEIR THERAPEUTIC APPLICATION SANOFI-AVENTIS (FR) 2007-08-09 US disclosed
EP-1776347-A1 SULPHONAMIDE DERIVATIVES, THEIR PREPARATION AND THEIR THERAPEUTIC APPLICATION Sanofi-Aventis (FR) 2007-04-25 EP disclosed
WO-2006024779-A1 SULPHONAMIDE DERIVATIVES, THEIR PREPARATION AND THEIR THERAPEUTIC APPLICATION SANOFI-AVENTIS (FR) 2006-03-09 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070185136-A1 SULPHONAMIDE DERIVATIVES, THEIR PREPARATION AND THEIR THERAPEUTIC APPLICATION HCRTR2, GIPR, SSTR2 NPC1 3528/4885ALDH1A1 2179/4885MAPT 3113/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.